Marksans Pharma board recommends final dividend of ₹0.90 per share

Marksans Pharma Ltd has fixed Thursday, August 20, 2026, as the record date to determine member eligibility for a final dividend of ₹0.90 per equity share. The Board of Directors recommended this dividend at its meeting held on May 26, 2026, for the financial year ended March 31, 2026. The payout is subject to the approval of shareholders at the upcoming Annual General Meeting (AGM). If approved, the dividend will be paid on or after Thursday, September 10, 2026, subject to deduction of tax at source.

The 34th AGM is scheduled for Thursday, August 27, 2026, at 11:00 a.m. IST via Video Conferencing. The Board meeting to consider the AGM date and record date commenced at 11:15 a.m. and concluded at 11:50 a.m. on July 03, 2026. The Notice of AGM and the Annual Report for FY26 will be sent to members electronically and made available on the company's website.

Financial Performance

The company reported a consolidated net profit of ₹4,200.64 million for the year ended March 31, 2026, compared to ₹3,826.19 million in the prior year. Revenue from operations increased to ₹29,509.38 million from ₹26,228.45 million in FY25. The financial results for FY26 were audited by MSKA & Associates LLP, which expressed an unmodified opinion.

Metric	FY26 (₹ in million)	FY25 (₹ in million)
Revenue from operations	29,509.38	26,228.45
Total Income	30,334.71	26,891.74
Total Expenses	24,729.16	21,852.07
Profit Before Tax	5,605.55	5,039.67
Net Profit	4,200.64	3,826.19

Key Developments

The Group operates a single reportable segment, Pharmaceuticals. During the year, the company incorporated two new wholly owned subsidiaries: Marksans Pharma (Europe) Limited in Ireland and Marksans (Canada) Inc. in Canada. The consolidated financial statements include the results of 12 audited subsidiaries and 3 unaudited subsidiaries. The total assets of the company stood at ₹38,609.02 million as of March 31, 2026, compared to ₹32,396.32 million in the previous year.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-5.13%	-8.86%	-3.56%	+46.32%	-0.24%	+184.67%

Marksans Pharma Ltd has completed the acquisition of 100% share capital of QliniQ B.V., a company based in the Netherlands. The transaction was finalized on June 16, 2026, as per the regulatory filing submitted to the National Stock Exchange of India Limited and BSE Limited. This acquisition marks a significant expansion of the company's operational reach in the European market.

The intimation was submitted under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had previously informed the exchanges about the proposed acquisition in a letter dated June 1, 2026. The completion of this process follows the necessary procedural approvals and due diligence.

Acquisition Details

The acquisition involves the purchase of the entire share capital of QliniQ B.V., thereby making it a wholly-owned subsidiary of Marksans Pharma Ltd. The financial details of the transaction were not disclosed in the regulatory filing. The move is expected to strengthen the company's presence in the Netherlands and broader European region.

Regulatory Compliance

The filing was signed by Harshavardhan Panigrahi, Company Secretary of Marksans Pharma Ltd. The intimation was submitted to ensure compliance with the SEBI regulations, requiring timely disclosure of material events. The company has requested the exchanges to take the intimation on record.

Strategic Implications

By acquiring QliniQ B.V., Marksans Pharma Ltd aims to leverage the Dutch company's capabilities to enhance its product offerings and market reach. The Netherlands serves as a strategic gateway to the European pharmaceutical market, known for its robust regulatory framework and high demand for quality healthcare products.